company background image
MPCI

Memphis Pharmaceuticals & Chemical IndustriesCASE:MPCI Stock Report

Market Cap

ج.م129.4m

7D

-4.4%

1Y

52.8%

Updated

21 Oct, 2021

Data

Company Financials
MPCI fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance3/6
Financial Health1/6
Dividends0/6

MPCI Overview

Memphis Pharmaceuticals & Chemical Industries produces and sells pharmaceutical products for human and veterinary use in Egypt.

Price History & Performance

Summary of all time highs, changes and price drops for Memphis Pharmaceuticals & Chemical Industries
Historical stock prices
Current Share Priceج.م23.01
52 Week Highج.م14.20
52 Week Lowج.م34.98
Beta0.35
1 Month Change-15.19%
3 Month Change-19.55%
1 Year Change52.79%
3 Year Change182.68%
5 Year Change131.49%
Change since IPO-23.86%

Recent News & Updates

Shareholder Returns

MPCIEG PharmaceuticalsEG Market
7D-4.4%-2.6%-0.8%
1Y52.8%0.1%11.1%

Return vs Industry: MPCI exceeded the EG Pharmaceuticals industry which returned -0.9% over the past year.

Return vs Market: MPCI exceeded the EG Market which returned 9.2% over the past year.

Price Volatility

Is MPCI's price volatile compared to industry and market?
MPCI volatility
MPCI Beta0.35
Industry Beta0.85
Market Beta1

Stable Share Price: MPCI is not significantly more volatile than the rest of EG stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: MPCI's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1940144n/ahttps://www.memphis.com.eg

Memphis Pharmaceuticals & Chemical Industries produces and sells pharmaceutical products for human and veterinary use in Egypt. The company offers human health products in various therapeutic areas, including anti-infective, CNS, dermatological, cardio vascular system, corticosteroid, vitamins and minerals, musculo-skeletal system, analgesic and antipyretic, respiratory system, genitourinary system, alimentary tract and metabolism, antihistaminic, antiparasites, and hormones. It also provides animal health products in powder form, as well as in oral and injectable solution forms.

Memphis Pharmaceuticals & Chemical Industries Fundamentals Summary

How do Memphis Pharmaceuticals & Chemical Industries's earnings and revenue compare to its market cap?
MPCI fundamental statistics
Market Capج.م129.43m
Earnings (TTM)ج.م37.56m
Revenue (TTM)ج.م505.67m

3.4x

P/E Ratio

0.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MPCI income statement (TTM)
Revenueج.م505.67m
Cost of Revenueج.م394.34m
Gross Profitج.م111.33m
Expensesج.م73.77m
Earningsج.م37.56m

Last Reported Earnings

Mar 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)6.68
Gross Margin22.02%
Net Profit Margin7.43%
Debt/Equity Ratio-13.1%

How did MPCI perform over the long term?

See historical performance and comparison

Valuation

Is Memphis Pharmaceuticals & Chemical Industries undervalued compared to its fair value and its price relative to the market?

3.45x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MPCI's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate MPCI's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MPCI is good value based on its PE Ratio (3.4x) compared to the EG Pharmaceuticals industry average (5.9x).

PE vs Market: MPCI is good value based on its PE Ratio (3.4x) compared to the EG market (11.6x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MPCI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MPCI has negative assets, so we can't compare its PB Ratio to the EG Pharmaceuticals industry average.


Future Growth

How is Memphis Pharmaceuticals & Chemical Industries forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

14.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Memphis Pharmaceuticals & Chemical Industries has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Memphis Pharmaceuticals & Chemical Industries performed over the past 5 years?

27.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MPCI has high quality earnings.

Growing Profit Margin: MPCI became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: MPCI has become profitable over the past 5 years, growing earnings by 27.7% per year.

Accelerating Growth: MPCI has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: MPCI has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10%).


Return on Equity

High ROE: MPCI's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Financial Health

How is Memphis Pharmaceuticals & Chemical Industries's financial position?


Financial Position Analysis

Short Term Liabilities: MPCI has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: MPCI has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: MPCI has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: MPCI's has negative shareholder equity, so we do not need to check if its debt has reduced over time.

Debt Coverage: MPCI's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: MPCI earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Memphis Pharmaceuticals & Chemical Industries's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MPCI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MPCI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MPCI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MPCI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: MPCI is not paying a notable dividend for the EG market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MPCI's dividend in 3 years as they are not forecast to pay a notable one for the EG market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.5yrs

Average management tenure


CEO

Memphis Pharmaceuticals & Chemical Industries has no CEO, or we have no data on them.


Leadership Team

Experienced Management: MPCI's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Memphis Pharmaceuticals & Chemical Industries's employee growth, exchange listings and data sources


Key Information

  • Name: Memphis Pharmaceuticals & Chemical Industries
  • Ticker: MPCI
  • Exchange: CASE
  • Founded: 1940
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ج.م129.431m
  • Shares outstanding: 5.63m
  • Website: https://www.memphis.com.eg

Number of Employees


Location

  • Memphis Pharmaceuticals & Chemical Industries
  • 7 Fadhli Street
  • St. Talaat Harb
  • Cairo
  • Egypt

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/21 14:31
End of Day Share Price2021/10/20 00:00
Earnings2021/03/31
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.